FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018421826> ?p ?o ?g. }

• W2018421826 endingPage "3359" @default.
• W2018421826 startingPage "3357" @default.
• W2018421826 abstract "In 1941, writing in the Lancet, R. D. Lawrence (1) noted that “[hypoglycemic] reactions differ so much from the original ones that patients become dangerously unaware of their onset.” This clinical description of impaired hypoglycemia awareness is still recognizable today, and we have become increasingly alert to its development after the publication of the landmark Diabetes Control and Complications Trial (DCCT) in 1993. The DCCT demonstrated that good glycemic control with intensive insulin therapy markedly reduced the risk of long-term microvascular complications of type 1 diabetes (T1D) (2) but that this came at the expense of a significant increase in the risk of biochemical and symptomatic hypoglycemia, whereas the risk of severe hypoglycemia increased 3-fold (3). Intensive insulin therapy was shown to reduce the glucose level at which hypoglycemic counterregulatory and symptomatic defense responses were initiated, significantly contributing to an individual’s risk of severe hypoglycemia (4). A number of studies in humans and animals then showed convincingly that prior exposure to hypoglycemia increased the threshold (lower glucose level) for hormone and symptom responses to subsequent hypoglycemia, which when combined with other counterregulatory defects in T1D (primarily the loss of pancreatic -cell glucagon secretion) was called the syndrome of hypoglycemia-associated autonomic failure (HAAF) (5). Studies, largely in animal models, have since helped inform us about how and where hypoglycemia is sensed in the body (6). However, as pointed out by Amiel (7) in a recent review, our ability to actually prevent the development of HAAF other than through strenuous efforts to avoid hypoglycemia is very limited, more often than not just leading to a period of more relaxed glucose control. In light of this, the report by Vele et al. (8) in this issue of the JCEM, in which the nonspecific opioid receptor antagonist naloxone prevented the development of HAAF in individuals with intensively treated T1D who were studied using an established experimental model, is an important one. Eight subjects with T1D (age, 34 7 yr; duration of diabetes, 12 3 yr), all treated with insulin pumps and with good glycemic control (glycosylated hemoglobin, 7.3 1.1%), took part in three different studies in random order and each separated by at least 5 wk. Each study required the subject to attend on 2 consecutive days. On d 1, each subject underwent two 90-min hyperinsulinemic glucose clamp studies separated by 60 min. The conditions induced were euglycemia (90 mg/dl) or hypoglycemia (60 mg/dl), the latter with (N ) or without (N ) a concomitant infusion of naloxone. On d 2, all subjects underwent a stepped (90, 80, 70, and 60 mg/dl) hypoglycemic clamp study where each glucose plateau was maintained for 50 min, and blood samples were taken for measurement of counterregulatory hormones and glucose turnover. The investigators found as expected that two episodes of antecedent hypoglycemia (control euglycemia vs. N ) resulted in a significant suppression of the epinephrine response to d 2 hypoglycemia, and this was associated with reduced whole body glucose production and increased glucose uptake, hallmarks of HAAF in T1D. In contrast, coinfusion of naloxone during d 1 hypoglycemia (N ) completely prevented the hypoglycemia-induced decrements in epinephrine secretion and hepatic glucose production, as well as the increase in whole body glucose uptake. These findings to a large extent replicate those of a similar study in nondiabetic subjects reported previously in this journal by the same group (9), and the authors" @default.
• W2018421826 created "2016-06-24" @default.
• W2018421826 creator A5049374974 @default.
• W2018421826 date "2011-11-01" @default.
• W2018421826 modified "2023-09-27" @default.
• W2018421826 title "The Response to Hypoglycemia: A Role for the Opioid System?" @default.
• W2018421826 cites W1987132873 @default.
• W2018421826 cites W1987781568 @default.
• W2018421826 cites W1994987925 @default.
• W2018421826 cites W2015912378 @default.
• W2018421826 cites W2030958701 @default.
• W2018421826 cites W2033641935 @default.
• W2018421826 cites W2058439802 @default.
• W2018421826 cites W2059802140 @default.
• W2018421826 cites W2072878208 @default.
• W2018421826 cites W2075761723 @default.
• W2018421826 cites W2087112828 @default.
• W2018421826 cites W2093783896 @default.
• W2018421826 cites W2109582726 @default.
• W2018421826 cites W2128502852 @default.
• W2018421826 cites W2130634848 @default.
• W2018421826 cites W2145935162 @default.
• W2018421826 cites W2769264260 @default.
• W2018421826 cites W4252271922 @default.
• W2018421826 doi "https://doi.org/10.1210/jc.2011-2540" @default.
• W2018421826 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22058380" @default.
• W2018421826 hasPublicationYear "2011" @default.
• W2018421826 type Work @default.
• W2018421826 sameAs 2018421826 @default.
• W2018421826 citedByCount "5" @default.
• W2018421826 countsByYear W20184218262015 @default.
• W2018421826 countsByYear W20184218262017 @default.
• W2018421826 countsByYear W20184218262019 @default.
• W2018421826 countsByYear W20184218262022 @default.
• W2018421826 crossrefType "journal-article" @default.
• W2018421826 hasAuthorship W2018421826A5049374974 @default.
• W2018421826 hasBestOaLocation W20184218261 @default.
• W2018421826 hasConcept C126322002 @default.
• W2018421826 hasConcept C134018914 @default.
• W2018421826 hasConcept C170493617 @default.
• W2018421826 hasConcept C2780668416 @default.
• W2018421826 hasConcept C2781063702 @default.
• W2018421826 hasConcept C555293320 @default.
• W2018421826 hasConcept C71924100 @default.
• W2018421826 hasConceptScore W2018421826C126322002 @default.
• W2018421826 hasConceptScore W2018421826C134018914 @default.
• W2018421826 hasConceptScore W2018421826C170493617 @default.
• W2018421826 hasConceptScore W2018421826C2780668416 @default.
• W2018421826 hasConceptScore W2018421826C2781063702 @default.
• W2018421826 hasConceptScore W2018421826C555293320 @default.
• W2018421826 hasConceptScore W2018421826C71924100 @default.
• W2018421826 hasIssue "11" @default.
• W2018421826 hasLocation W20184218261 @default.
• W2018421826 hasLocation W20184218262 @default.
• W2018421826 hasOpenAccess W2018421826 @default.
• W2018421826 hasPrimaryLocation W20184218261 @default.
• W2018421826 hasRelatedWork W1992894626 @default.
• W2018421826 hasRelatedWork W2000722110 @default.
• W2018421826 hasRelatedWork W2057434408 @default.
• W2018421826 hasRelatedWork W2076974163 @default.
• W2018421826 hasRelatedWork W2080068238 @default.
• W2018421826 hasRelatedWork W2092734860 @default.
• W2018421826 hasRelatedWork W2121421331 @default.
• W2018421826 hasRelatedWork W2121663374 @default.
• W2018421826 hasRelatedWork W2138496896 @default.
• W2018421826 hasRelatedWork W4249776206 @default.
• W2018421826 hasVolume "96" @default.
• W2018421826 isParatext "false" @default.
• W2018421826 isRetracted "false" @default.
• W2018421826 magId "2018421826" @default.
• W2018421826 workType "article" @default.